Insights about U.S. Stocks that landed in the Green-Zone during Wednesday’s trade, are depicted

Olin Corporation (NYSE:OLN)’s shares picked up 7.65%, and closed at $30.25, hitting new 52-week high of $30.25.

Olin Corp. (OLN), declared that it is lifting the force majeure declared on February 10, 2015 for chlorine and chemically pure salt from its McIntosh, Alabama facility. Normal production of chlorine and chemically pure salt from that plant has now resumed. Olin remains on order control for chlorine due to supply tightness in its overall system.

Olin Corporation is a manufacturer concentrated in three business segments: Chlor Alkali Products, Chemical Distribution and Winchester. Chlor Alkali Products, with eight U.S. manufacturing facilities and one Canadian manufacturing facility, produces chlorine and caustic soda, hydrochloric acid, hydrogen, bleach products and potassium hydroxide.

Sanchez Energy Corp (NYSE:SN), raised 7.46%, and closed at $13.98.

Sanchez Energy Corporation (SN), declared the Corporation’s operating and financial results for the fourth quarter and full-year 2014, which comprised of the following highlights:

HIGHLIGHTS FOR FOURTH QUARTER 2014:

• Record proceeds of $172.5 million, an raise of 33% over the preceding year
• Record production of 4,039 MBOE; an average of 43,897 BOE/D
• Adjusted EBITDA, a non-GAAP financial measure defined below, of $133.7 million, an raise of 36% over the preceding year
• Current production of about 44,000 BOE/D
• Estimated proved reserves of about 135 MMBOE at December 31, 2014, up more than 7 MMBOE, or 6%, from about 127 MMBOE at September 30, 2014, and up over 76 MMBOE, or 129%, from about 59 MMBOE at December 31, 2013
• First quarter and full year 2015 production guidance range re-affirmed at 40,000 to 44,000 BOE/D
• Capital plan for 2015 re-affirmed at $600 - $650 million
• Net loss attributable to ordinary stockholders of $66.1 million, which comprises a non-cash after tax impairment charge of $139.0 million due to the decline in commodity prices
• Liquidity of $774 million as of December 31, 2014 comprising of $474 million in cash and cash equivalents and a $650 million unused accessible borrowing base with a $300 million elected commitment amount under our revolving credit facility.

Sanchez Energy Corporation, an independent exploration and production corporation, focuses on the attainment, exploration, and development of unconventional oil and natural gas resources in the onshore U.S.

Raptor Pharmaceutical Corp (NASDAQ:RPTP), enhanced 7.18%, and closed at $10.30.

Raptor Pharmaceuticals Corp. (RPTP), stated financial results for the fourth quarter and year ended December 31, 2014 and offered an update on recent corporate developments.

Global net product sales for PROCYSBI(R) (cysteamine bitartrate) delayed-release capsules were $17.3 million for the fourth quarter ended December 31, 2014 contrast to $10.2 million for the same period in 2013. Global net product sales for PROCYSBI for the full year 2014 were $69.5 million contrast to $16.9 million for the same period in 2013. Global net product sales in 2014 came in at the top end of the corporation’s guidance range of $65 to $70 million.

Raptor stated a net loss on a GAAP basis of $18.9 million for the fourth quarter, or $0.29 per share, and a net loss of $52.5 million, or $0.83 per share, for the full year.

The corporation made several key hires in the fourth quarter of 2014 and in January 2015 to build the executive administration team and designated two new members to the Board of Directors in January 2015.

Raptor Pharmaceuticals Corp. (RPTP), is a global biopharmaceutical corporation focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The corporation is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington’s disease (HD), nonalcoholic steatohepatitis (NASH), Leigh syndrome and other mitochondrial diseases.

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), enhanced 7.16%, and closed at $1.05.

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical corporation focused on developing breakthrough treatments for human disease, updated its drug development progress and stated financial results for the three months and year ended December 31, 2014.

In October 2014, Lexicon accomplished a partnership contract with Ipsen Pharma SAS for the commercialization of telotristat etiprate, with a focus on carcinoid syndrome, in markets outside the United States, Canada and Japan. Under the contract, Lexicon is eligible to receive up to about $145 million in aggregate upfront and milestone payments, counting an upfront payment of $23 million. In addition, Lexicon is entitled to receive royalties on net sales of telotristat etiprate by Ipsen.

Also in the fourth quarter of 2014, Lexicon accomplished concurrent debt and equity financings that resulted in gross proceeds of $293.4 million. After fees and offering expenses, the financings resulted in net proceeds of $286.0 million and are reflected in the corporation’s financial results as of December 31, 2014. In the aggregate, the financings compriseed of the issuance of about 204.9 million shares of ordinary stock, with gross proceeds of $205.9 million, and $87.5 million in aggregate principal amount of 5.25% convertible senior notes due 2021.

Lexicon Pharmaceuticals, Inc. (LXRX), is a biopharmaceutical corporation focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon’s research team.